JP6807337B2 - ミトコンドリア治療剤としてのフェノチアジン類似体 - Google Patents

ミトコンドリア治療剤としてのフェノチアジン類似体 Download PDF

Info

Publication number
JP6807337B2
JP6807337B2 JP2017561611A JP2017561611A JP6807337B2 JP 6807337 B2 JP6807337 B2 JP 6807337B2 JP 2017561611 A JP2017561611 A JP 2017561611A JP 2017561611 A JP2017561611 A JP 2017561611A JP 6807337 B2 JP6807337 B2 JP 6807337B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
aryl
cycloalkyl
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017561611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505228A (ja
JP2018505228A5 (enExample
Inventor
シドニー ヘクト，
シドニー ヘクト，
オマール クドール，
オマール クドール，
サンディパン ロイ チョウドリー，
サンディパン ロイ チョウドリー，
インドラジット バンディオパダイ，
インドラジット バンディオパダイ，
Original Assignee
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ, アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ filed Critical アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ
Publication of JP2018505228A publication Critical patent/JP2018505228A/ja
Publication of JP2018505228A5 publication Critical patent/JP2018505228A5/ja
Application granted granted Critical
Publication of JP6807337B2 publication Critical patent/JP6807337B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017561611A 2015-02-17 2016-02-17 ミトコンドリア治療剤としてのフェノチアジン類似体 Expired - Fee Related JP6807337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117205P 2015-02-17 2015-02-17
US62/117,205 2015-02-17
PCT/US2016/018233 WO2016133995A1 (en) 2015-02-17 2016-02-17 Phenothiazine analogues as mitochondrial therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020169793A Division JP7113055B2 (ja) 2015-02-17 2020-10-07 ミトコンドリア治療剤としてのフェノチアジン類似体

Publications (3)

Publication Number Publication Date
JP2018505228A JP2018505228A (ja) 2018-02-22
JP2018505228A5 JP2018505228A5 (enExample) 2020-04-09
JP6807337B2 true JP6807337B2 (ja) 2021-01-06

Family

ID=56692740

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017561611A Expired - Fee Related JP6807337B2 (ja) 2015-02-17 2016-02-17 ミトコンドリア治療剤としてのフェノチアジン類似体
JP2020169793A Expired - Fee Related JP7113055B2 (ja) 2015-02-17 2020-10-07 ミトコンドリア治療剤としてのフェノチアジン類似体
JP2022118006A Pending JP2022141896A (ja) 2015-02-17 2022-07-25 ミトコンドリア治療剤としてのフェノチアジン類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020169793A Expired - Fee Related JP7113055B2 (ja) 2015-02-17 2020-10-07 ミトコンドリア治療剤としてのフェノチアジン類似体
JP2022118006A Pending JP2022141896A (ja) 2015-02-17 2022-07-25 ミトコンドリア治療剤としてのフェノチアジン類似体

Country Status (7)

Country Link
US (3) US10472340B2 (enExample)
EP (1) EP3258938B1 (enExample)
JP (3) JP6807337B2 (enExample)
AU (3) AU2016220096B2 (enExample)
CA (1) CA2976776C (enExample)
DK (1) DK3258938T3 (enExample)
WO (1) WO2016133995A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976937C (en) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
WO2017218537A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
US12570622B2 (en) 2016-08-25 2026-03-10 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018129411A1 (en) * 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
FR3063495B1 (fr) 2017-03-02 2019-04-05 Provepharm Life Solutions Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
CN108484527B (zh) * 2018-04-27 2022-01-14 成都恒昊创新科技有限公司 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
US12502408B2 (en) 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
US12110313B2 (en) 2019-02-28 2024-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Engineered bacterial ribosome compositions and methods
WO2022171265A1 (en) * 2021-02-09 2022-08-18 Boehringer Ingelheim International Gmbh Modulators of complex i
CN119504646A (zh) * 2024-11-07 2025-02-25 长春工业大学 新型含有吩噻嗪结构药物小分子的合成及抗肿瘤活性研究

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476722A (en) 1966-08-15 1969-11-04 Goodrich Co B F Process for polymerizing acrylic acid esters
DE2315349A1 (de) 1973-03-28 1974-10-03 Bayer Ag Nicht verfaerbende alterungsschutzmittel
JPS5168569A (en) 1974-12-10 1976-06-14 Fuji Photo Film Co Ltd 2 2 44 torimechiru 66 hidorokishi 77 chikankuromanruino seizoho
FR2471052B1 (fr) * 1979-11-28 1985-10-11 Kuraray Co Photo-electrode pour cellule photo-electrochimique et son procede de fabrication
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2099868C (en) 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
AU5527196A (en) 1995-04-04 1996-10-23 Brigham And Women's Hospital Inhibiting retroviral replication
JP2001209176A (ja) 1999-04-02 2001-08-03 Fuji Photo Film Co Ltd 光重合性組成物およびそれを用いた記録材料
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
WO2002000683A2 (en) 2000-06-23 2002-01-03 Vanderbilt University Novel chain-breaking antioxidants
CA2452541A1 (en) 2001-07-20 2003-01-30 Eli Lilly And Company (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
KR20050012796A (ko) * 2002-06-17 2005-02-02 베리피케이션 테크놀로지스, 인코포레이티드 리더기의 빔에 일시적으로 반응하는 광학 매체복제-방지용 물질
CA2505603A1 (en) 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
US20060188866A1 (en) 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
JP2008534472A (ja) 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
US8268849B2 (en) 2007-09-25 2012-09-18 Board Of Regents Of The University Of Nebraska Multifunctional Antioxidants and methods of use thereof
CN105288619A (zh) 2008-04-04 2016-02-03 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
US8389583B2 (en) 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
ES2687177T3 (es) 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Inhibidores de radicales multifuncionales y su uso
US8785434B2 (en) * 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
EP2606022A2 (en) 2010-08-16 2013-06-26 Santhera Pharmaceuticals (Schweiz) AG Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2450893A1 (de) 2010-11-08 2012-05-09 Bayer MaterialScience AG Photopolymer-Formulierung zur Herstellung holographischer Medien mit hoch vernetzten Matrixpolymeren
WO2012125983A1 (en) * 2011-03-17 2012-09-20 Prosetta Antiviral Inc. Antiviral treatments
WO2012138713A2 (en) 2011-04-04 2012-10-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
KR101270160B1 (ko) 2011-05-16 2013-05-31 아주대학교산학협력단 가변색 이광자 형광프로브, 이를 이용한 미토콘드리아 내 티올 활성의 영상화 방법 및 이의 제조방법
WO2013120081A1 (en) 2012-02-10 2013-08-15 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University 1h- pyrrolo [2, 3 -b] pyridine derivatives and their use as radical quenchers
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
WO2014055629A1 (en) 2012-10-03 2014-04-10 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
EP2906207A4 (en) 2012-10-10 2016-10-26 Univ Arizona State MULTIFUNCTIONAL RADICAL QUENCHER
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
CA2976937C (en) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2017218537A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Also Published As

Publication number Publication date
DK3258938T3 (da) 2021-02-01
JP7113055B2 (ja) 2022-08-04
US20220081404A1 (en) 2022-03-17
EP3258938B1 (en) 2020-12-02
AU2020202836B2 (en) 2020-12-17
AU2021201137A1 (en) 2021-03-11
US20200115355A1 (en) 2020-04-16
JP2021006573A (ja) 2021-01-21
EP3258938A4 (en) 2018-10-31
AU2020202836A1 (en) 2020-05-21
AU2016220096A1 (en) 2017-08-31
US20180065941A1 (en) 2018-03-08
WO2016133995A1 (en) 2016-08-25
CA2976776C (en) 2023-06-20
JP2018505228A (ja) 2018-02-22
US10472340B2 (en) 2019-11-12
AU2016220096B2 (en) 2020-01-30
JP2022141896A (ja) 2022-09-29
US11034662B2 (en) 2021-06-15
CA2976776A1 (en) 2016-08-25
EP3258938A1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
JP2021006573A (ja) ミトコンドリア治療剤としてのフェノチアジン類似体
US8952025B2 (en) Multifunctional radical quenchers and their uses
US9102626B2 (en) Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
Azimi et al. Discovery of imidazopyridines containing isoindoline-1, 3-dione framework as a new class of BACE1 inhibitors: design, synthesis and SAR analysis
EP2891649B1 (en) Prolylhydroxylase inhibitors and methods of use
US9334250B2 (en) Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
US10669287B2 (en) Curcumin-boron complex and pharmaceutical containing same
JP6770534B2 (ja) 治療用化合物
US20250313576A1 (en) Compound for photooxygenation catalyst and medicinal composition containing same
US20200360366A1 (en) Prolylhydroxylase/atf4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
WO2021145368A1 (ja) フェノチアジン骨格を有する光酸素化触媒化合物及びこれを含有する医薬
KR20230145971A (ko) 티아졸리딘 기반의 신규 화합물 및 그의 용도
WO2021112122A1 (ja) 光酸素化触媒化合物及びこれを含有する医薬
Chojnacki Novel Compounds as Potential Alzheimer's Disease Therapeutics and Inhibitors of the Nlrp3 Inflammasome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191225

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201207

R150 Certificate of patent or registration of utility model

Ref document number: 6807337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees